5. Summary of Treatment
1.Resection is the only chance for a cure, and
resectable patients show undergo surgery
without delay followed by adjuvant therapy
2.Borderline resectable patients may benefit
from neoadjuvant therapy and then surgery
3.Unresectable patients may benefit from
chemotherapy or chemoradiation
4.Metastatic disease may benefit from
chemotherapy or other palliative treatments
6. Survival
Surgery offers the only cure, but only 10-20%
are candidates and the 5 year survival is only
20% and median 13-20 months
Locally advanced the median survival is 8-14
months
Up to 60% already have metastases and
survival of 4 to 6 months
7. Patterns of Failure after
Surgery
After surgery local relapse rate of 50
– 86%
and distant recurrence rate of 40 –
90%
8. RTOG 9704
postOp FU then chemoradiation versus
Gemcitabine then chemoradiation
(50.4Gy)
Slight advantage to the Gemzar arm for
head of pancreas group: median survival
of 20.5 months versus 17.1 months and
long term 22%/5y versus 18%/5y
9. Is there a proven role for postOp
radiation?
• European studies (CONKO 001 Trial, EORTC
Trial, ESPAC-1 showed benefit from
chemotherapy but no benefit or in fact harm
from including radiation and so they favor
chemotherapy alone
• American Trials (GITSG) showed benefit and
favor including radiation
10. Benefits from Adjuvant Radiation
GITSG
postOp 40Gy + 5FU versus observation
The radiation arm had better median survival (20 mos versus 11 mos)
and 2 year survival 20% versus 10%
EORTC
postOp 5FU versus chemorad (40Gy in split course) and better 2Y
survival in radiation arm: 34% versus 26%
NCDB review
chemoradiation improved survival (HR .784) but no chemoRx (1.08)
Hopkins/ Mayo Clinic Review (Hsu, 2008) n = 1.045
Adjuvant 5FU/XRT improved survival from 16.3 months to 22.5
months
11. Adjuvant Radiotherapy and Chemotherapy
for Pancreatic Carcinoma: The Mayo Clinic
Experience (1975-2005)
review 472 consecutive patients who
underwent complete resection with negative
margins (R0) for invasive carcinoma (T1-3N0-
1M0)
Surgery S + Chemoradiation
Overall survival 19.2 mos 25.2 mos
Survival 39%/2y 50%/2y
15%/5y 28%/5y
JCO July 20, 2008:3511-3516
12. Adjuvant Chemotherapy and Radiation Large,
Prospectively Collected Database at the Johns
Hopkins Hospital /The final cohort includes 616
patients.
JCO July 20, 2008:3503-3510
Surgery S + Chemoradiation
Median Survival 14.4 mos 21.2 mos
Survival 31.9%/2y 43.9%/2y
15.4%/5y 20.1%/5y
13. Study number median 2y 5y
GITSG
chemoradiation 21 20.0 mos 42% 15%
observation 22 10.9 mos 15% 5%
chemoradiation 30 18.0 mos 46% 17%
EORTC
chemoradiation 110 21.6 mos 51% 25%
observation 108 19.2 mos 41% 22%
ESPAC-1
chemotherapy 147 20.1 mos 40% 21%
no chemo 142 15.5 mos 30% 8%
chemoradiation 145 15.9 mos 29% 10%
no chemorad. 144 17.9 mos 41% 20%
RTOG-9704
gemzar – chemorad 187 20.5 mos 31%/3 22%
5-FU – chemorad 201 17.2 mos 22%/3y 18%
Prospective Trials of Adjuvant Therapy
14. RTOG 0848 Adjuvant
Step 1: Adjuvant chemotherapy: (Arm1
Gemcitabine X 5 or Arm 2
Gemcitabine + Erlotinib X 5))
Step2: In no progression then: (Arm 3
one more cycle of chemo or Arm 2 1
cycle then chemoradiation with either
capecitabine or 5-FU)
Radiation dose is 1.8Gy X 28 (50.4Gy)
17. Summary of Treatment
1.Resection is the only chance for a cure, and
resectable patients show undergo surgery
without delay followed by adjuvant therapy
2.Borderline resectable patients may benefit
from neoadjuvant therapy and then surgery
3.Unresectable patients may benefit from
chemotherapy or chemoradiation
4.Metastatic disease may benefit from
chemotherapy or other palliative treatments
18. Neoadjuvant Therapy (chemo or
radiation prior to surgery)
-About 1/3 of patients have a long delay after
surgery getting started on PostOp therapy
- 20-40% who get preOp will be found to
develop Mets and avoid surgery
-PreOp may increase the number of surgical
candidates
-No good randomized Trials
-Some trials the 5 year survival in those
undergoing a curative resection in the 32 – 36%
range
19. SEER Data Base
3,885 Resectable Pancreas
Cancer
Treatment Number Median Survival
Neoadjuvant XRT 70 (2%) 23 months
PostOp XRT 1,478 (38%) 17 months
Surgery Only 2,337 (60%) 12 months
. Int J Radiat Oncol Biol Phys2008;72(4):1128–1133.
20. Summary of Treatment
1.Resection is the only chance for a cure, and
resectable patients show undergo surgery
without delay followed by adjuvant therapy
2.Borderline resectable patients may benefit
from neoadjuvant therapy and then surgery
3.Unresectable patients may benefit from
chemotherapy or chemoradiation
4.Metastatic disease may benefit from
chemotherapy or other palliative treatments
22. Survival in ECOG Trial
JCO November 1, 2011vol. 29 no. 31 4105-4112
Chemo + Radiation
Chemo
23. Median Survival in Months
Inoperable Pancreas Cancer
Gemzar Alone 9.1 – 9.9
Gemzar + Radiation 11.3 – 11.9
JCO November 1, 2011vol. 29 no. 31 4105-4112
24. RTOG 1201 Unresectable
Three Arms ChemoRx Radiation
1 gemcitabine X 12w 63Gy (IMRT) + capecitabine
2 gemcitabine X 12w 50.4Gy (3D) + capecitabine
3 FOLFIRINOX X 12w 50.4Gy (3D) + capecitabine
IMRT Dose is 2.25Gy X 28 (63Gy) / 3D Dose is 1.8 Gy X 28 (50.4Gy)
95% of the PTV must get 95% of the prescribed dose and the Dmax to
0.03cc is no higher than 110% of the prescription dose
38. Computer Reconstruction from the CT Scan
Multiple structures (Liver, Stomach, Small Bowel, Colon, Spinal
Cord, Kidneys) can all be effected by the radiation field
42. Radiation
1.Patients are usually treated daily,
Monday through Friday for about 5
weeks
2.Dose of inoperable patients is 45-
54Gy (1.8 – 2.5Gy/fx) or 36Gy (2.4
fx)
3.PostOp patients 45-46Gy (1.8 –
2Gy/fx) with possible 5 – 9Gy
boost
47. Side Effects of Pancreas
Radiation
• Fatigue
• Loss of appetite
• Diarrhea
• Skin Irritation
Long Term:
Depending on the dose to other organs, there
is a small risk of bowel damage or decreased
function from the liver or kidneys